ISARIC - Coronavirus Clinical Characterisation Consortium (ISARIC-4C)

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Total publications:135 publications

Grant number: MC_PC_19059

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Principle Investigator

  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    University of Edinburgh
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory


  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



This COVID-19 Rapid Response award is jointly funded (50:50) between the Medical Research Council and the National Institute for Health Research. The figure displayed is the total award amount of the two funders combined, with each partner contributing equally towards the project. It seems highly likely that SARS-CoV-2 will cause disease and mortality unprecedented in modern times. Despite rapid publication of data from China, many unanswered questions remain that have immediate bearing on control and treatment of COVID-19: • Pathogen: how does transmission occur and over what period? What features of the virus drive transmission and severity? • Host: How can diagnosis be improved? How can severity be predicted? Does prior immunity to other viruses worsen disease severity? How does (non)pulmonary organ injury occur? Can therapy be tailored according to disease mechanisms? Which bacterial or fungal co-infections contribute to critical illness? This is a new disease. There is a high chance that clinical trials will fail to detect therapeutic effects, by enrolling at the wrong time, or missing key subgroups or endpoints. Deep biological phenotyping can mitigate these risks, providing rapid, efficient clinical evidence. Our response has been planned and tested over the past 8 years within the International Severe Acute Respiratory Infection Consortium (ISARIC). We will recruit at least the first 1300 consenting UK patients, and 1000 suspected cases, as the base of a coordinated national response, using our established, internationally-harmonized protocol (ISARIC Clinical Characterisation Protocol) to: • Provide a unified foundation for clinical trials, enriching design and interpretation • Provide an open-access platform for evaluation of diagnostics and therapeutics • Establish a sample repository with independently-managed availability to researchers and to industry. • Use real-time data to inform the response by funders, public health and hospitals ISARIC-4C is a consortium of experts with a proven track record of high-quality outbreak research. We have already recruited 87% of cases reported in the UK.

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

Sex differences in post-acute neurological sequelae of SARS-CoV-2 and symptom resolution in adults after coronavirus disease 2019 hospitalization: an international multi-centre prospective observational study.

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.

Delayed mucosal anti-viral responses despite robust peripheral inflammation in fatal COVID-19.

A clinical approach to the investigation and management of long COVID associated neuropathic pain.

Global Landscape of Encephalitis: Key Priorities to Reduce Future Disease Burden.

International Pediatric COVID-19 Severity Over the Course of the Pandemic.

Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera.

A multi-country analysis of COVID-19 hospitalizations by vaccination status.

Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry.